Previous 10 | Next 10 |
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2020 and recent corporate highlights. ...
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in the H.C. Wain...
Checkpoint Therapeutics (CKPT) founded by Fortress Biotech (FBIO) has announced the formation of an independent scientific advisory board, a five-member group of experts in immunotherapy, lung, and skin cancers.The advisory board will work closely with Checkpoint leadership to further develop...
Penny Stocks To Buy According To Analysts Looking for penny stocks to buy right now? You’re obviously not alone. But there’s a bit of a cautious tone in the stock market today after last week’s rout. Nearly every sector pulled back, closing out February on uncer...
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the formation of an independent Scientific Advisory Board comprising leaders in the fields of...
Today, we take our first in depth look at a small immuno-oncology concern based out of New York City. Like so many in this space after they debut on the markets, the stock is in 'Busted IPO' territory after coming public late in 2016. However, the company has a diverse pipeline th...
Will These 5 Biotech Penny Stocks Rally Under a New President? As the biotech industry continues its surge, many investors wonder which biotech penny stocks could be worth watching right now. This is a tough question to answer in only a few sentences, as there are plenty of implicat...
Checkpoint Therapeutics ([[CKPT]] +8.2%) was initiated at Cantor Fitzgerald with an Overweight rating, PT $16.Analyst Jennifer Kim believes that the potential peak sales opportunity for cosibelimab is underappreciated.Quick look at pipeline:Analyst believes upwards earnings estimate revisions...
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual ...
Checkpoint Therapeutics (CKPT) entered into an equity distribution agreement dated December 17, 2020, providing for an at-the-market ("ATM") equity offering program, pursuant to a controlled equity offering sales agreement between the Company, Cantor Fitzgerald, Ladenburg...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...